[Form 3] BioLineRx Ltd. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

BioLineRx Ltd. director Aharon Schwartz filed an initial ownership report showing direct holdings of 3,705,000 Ordinary Shares. He also holds multiple fully vested and time-vested employee stock options under the company’s 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.92 per share and expirations extending through 2034. A large October 2024 grant covers 2,055,000 underlying Ordinary Shares, of which 856,200 were vested at appointment and the remaining 1,198,800 are scheduled to vest in seven equal quarterly installments, subject to continued service.

Insider Trade Summary

11 transactions reported

Mixed 11 txns

Insider Schwartz Aharon

Role Director

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Ordinary Shares, 0.1 NIS per share	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 49,800 shares (Direct); Ordinary Shares, 0.1 NIS per share — 3,705,000 shares (Direct)

Footnotes (1)

1. Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

Key Figures

Ordinary Shares held: 3,705,000 shares Option exercise price: $0.8370 per share Option exercise price: $0.9200 per share +5 more

8 metrics

Ordinary Shares held 3,705,000 shares Directly held Ordinary Shares as of Form 3

Option exercise price $0.8370 per share Employee Stock Option expiring July 5, 2026

Option exercise price $0.9200 per share Employee Stock Option expiring July 5, 2027

Large 2019 option grant 199,800 underlying shares at $0.3560 Option expiring July 2, 2029

Large 2022 option grant 1,080,000 underlying shares at $0.0850 Option expiring July 3, 2032

October 2024 option grant 2,055,000 underlying shares at $0.0520 Option expiring August 14, 2034

Vested portion of 2024 grant 856,200 options Vested as of appointment date October 1, 2024

Unvested portion of 2024 grant 1,198,800 options To vest in seven equal quarterly installments

Key Terms

Employee Stock Option (Right to Buy), 2003 Amended and Restated Share Incentive Plan, Section 102 of the Israeli Tax Ordinance, Ordinary Shares, +2 more

6 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

2003 Amended and Restated Share Incentive Plan financial

"Options granted under the 2003 Amended and Restated Share Incentive Plan."

Section 102 of the Israeli Tax Ordinance financial

"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance"

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

fully vested financial

"This option grant is fully vested as of this date."

trustee financial

"securities issued to an employee ... must be registered in the name of a trustee"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Schwartz Aharon

(Last) (First) (Middle)

BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, 0.1 NIS per share	3,705,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	10/05/2016	07/05/2026	Ordinary Shares	49,800(12)	$0.837	D
Employee Stock Option (Right to Buy)(1)(3)	10/05/2017	07/05/2027	Ordinary Shares	19,800(12)	$0.92	D
Employee Stock Option (Right to Buy)(1)(4)	10/05/2018	07/05/2028	Ordinary Shares	19,800(12)	$0.894	D
Employee Stock Option (Right to Buy)(1)(5)	10/02/2019	07/02/2029	Ordinary Shares	199,800(12)	$0.356	D
Employee Stock Option (Right to Buy)(1)(6)	10/02/2020	07/02/2030	Ordinary Shares	79,800(12)	$0.369	D
Employee Stock Option (Right to Buy)(1)(7)	10/02/2021	07/02/2031	Ordinary Shares	79,800(12)	$0.388	D
Employee Stock Option (Right to Buy)(1)(8)	10/03/2022	07/03/2032	Ordinary Shares	1,080,000(12)	$0.085	D
Employee Stock Option (Right to Buy)(1)(9)	10/03/2023	07/03/2033	Ordinary Shares	360,000(12)	$0.081	D
Employee Stock Option (Right to Buy)(1)(10)	10/03/2024	07/03/2032	Ordinary Shares	360,000(12)	$0.085	D
Employee Stock Option (Right to Buy)(1)(11)	01/01/2025	08/14/2034	Ordinary Shares	2,055,000(12)	$0.052	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date.

3. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date.

4. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date.

5. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date.

6. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date.

7. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date.

8. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date.

9. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date.

10. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date.

11. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

12. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

	/s/ Aharon Schwartz	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioLineRx (BLRX) Form 3 filing by Aharon Schwartz show?

The Form 3 shows director Aharon Schwartz’s initial holdings in BioLineRx, including 3,705,000 Ordinary Shares and several employee stock option grants with various exercise prices and expiration dates under the company’s 2003 Amended and Restated Share Incentive Plan.

How many BioLineRx (BLRX) ordinary shares does Aharon Schwartz directly hold?

Aharon Schwartz directly holds 3,705,000 Ordinary Shares of BioLineRx. These shares are reported as directly owned, separate from his employee stock option positions, which give him the right to buy additional Ordinary Shares at preset exercise prices if he chooses to exercise.

What stock option grants are reported for Aharon Schwartz in BioLineRx (BLRX)?

The filing lists multiple Employee Stock Option (Right to Buy) grants over several years, with exercise prices between $0.052 and $0.92 per share. Each grant is tied to specific expiration dates extending from 2026 through 2034, covering defined numbers of underlying Ordinary Shares.

What is notable about the October 2024 BioLineRx (BLRX) option grant to Aharon Schwartz?

The October 2024 grant covers 2,055,000 underlying Ordinary Shares at a $0.052 exercise price. Footnotes state 856,200 options were vested at appointment and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.

Under which plan were Aharon Schwartz’s BioLineRx (BLRX) options granted?

Footnotes state options were granted under the 2003 Amended and Restated Share Incentive Plan. To qualify for tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with this plan must be registered in the name of a trustee.

Are Aharon Schwartz’s BioLineRx (BLRX) options vested or subject to vesting?

Several option grants are described as fully vested as of their grant dates between 2016 and 2024. The large October 2024 grant is partially vested, with 1,198,800 options scheduled to vest in seven equal quarterly installments if he continues serving the company.